Brief: Theranexus Receives European Patent Protecting THN201
09/10/2018 06:52
Oct 9 (Reuters) - THERANEXUS SA ALTHX.PA :
* ANNOUNCES THE ISSUE OF A NEW EUROPEAN PATENT COVERING
CANDIDATE
THN201
* PATENT IS VALID UNTIL 2032
Source text for Eikon: urn:newsml:reuters.com:*:nACT55428
Further company coverage: ALTHX.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease